Trimipramine
As of the edition of 20 October 2026, Trimipramine is a small molecule: marketed, first approved in 1962 (CH); acts on ADRA1A, ADRA1B and ADRA1D and 5 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Surmontil
- First approved
- 10 July 1962 (CH)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- NEURAXPHARM FRANCE; 4 holders in all
- Registered trials
- 3, 1 stopped early
- Disease areas
- Mental health; Cancer; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| DRD2 | Dopamine receptor D2 | P14416 |
| SLC6A2 | Sodium-dependent noradrenaline transporter | P23975 |
| ADRA1D | Alpha-1D adrenergic receptor | P25100 |
| HTR2A | 5-hydroxytryptamine receptor 2A | P28223 |
| HTR2C | 5-hydroxytryptamine receptor 2C | P28335 |
| ADRA1A | Alpha-1A adrenergic receptor | P35348 |
| HRH1 | Histamine H1 receptor | P35367 |
| ADRA1B | Alpha-1B adrenergic receptor | P35368 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 3 |